Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

23.53
-1.1700-4.74%
Post-market: 23.530.00000.00%18:46 EDT
Volume:294.10K
Turnover:7.01M
Market Cap:699.58M
PE:-28.23
High:24.65
Open:24.60
Low:23.44
Close:24.70
52wk High:44.28
52wk Low:14.59
Shares:29.73M
Float Shares:25.11M
Volume Ratio:0.97
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8334
EPS(LYR):-0.8334
ROE:-5.21%
ROA:-2.56%
PB:1.49
PE(LYR):-28.23

Loading ...

Castle Biosciences CEO Derek Maetzold Reports Disposal of Common Shares

Reuters
·
Feb 06

Castle Biosciences Inc. to Release Fourth Quarter and Full-Year Financial Results and Host Conference Call

Reuters
·
Feb 05

Castle Biosciences price target raised to $50 from $36 at KeyBanc

TIPRANKS
·
Jan 30

Castle Biosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 27

SciBase Holding AB Secures 82.7% Subscription in SEK 83 Million Rights Issue

Reuters
·
Jan 22

Castle Biosciences Is Maintained at Buy by Lake Street

Dow Jones
·
Jan 12

Castle Biosciences Expects 2025 Revenue to Exceed $340 Million

Reuters
·
Jan 12

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

THOMSON REUTERS
·
Jan 12

Castle Biosciences Inc - 2025 Total Revenue Expected to Exceed $340 Mln, Above Previously Guided Range of $327-335 Mln

THOMSON REUTERS
·
Jan 12

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Jan 08

Castle Biosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 06

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Dec 30, 2025

Assessing Castle Biosciences (CSTL) Valuation After New Uveal Melanoma Data and Renewed Analyst Optimism

Simply Wall St.
·
Dec 25, 2025

Castle Biosciences (CSTL) Is Up 6.5% After New Melanoma Data Validates DecisionDx Tests

Simply Wall St.
·
Dec 24, 2025

Castle Biosciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 22, 2025

Castle Biosciences COO Kristen M. Oelschlager Reports Disposal of Common Shares

Reuters
·
Dec 20, 2025

BRIEF-Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Dec 19, 2025

Castle Biosciences Grants RSUs to 83 New Employees under Inducement Plan

Reuters
·
Dec 19, 2025

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 19, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Dec 18, 2025